Variable | level | Event | Total | Univariate mode | Multivariate model | ||||
---|---|---|---|---|---|---|---|---|---|
HR | 95%CI | P | HR | 95%CI | P | ||||
PABC | Yes | 16 | 63 | 2.340 | 1.164 ~ 4.701 | 0.017 | 0.971 | 0.437 ~ 2.158 | 0.943 |
No | 16 | 126 | 1 | Â | Â | Â | Â | Â | |
Age at diagnosis |  ≤ 35 | 23 | 133 | 1.125 | 0.520 ~ 2.437 | 0.765 |  |  |  |
 > 35 | 9 | 56 | 1 |  |  |  |  |  | |
Family history | Yes | 6 | 18 | 2.430 | 0.997 ~ 5.925 | 0.051 | 2.204 | 0.831 ~ 5.844 | 0.112 |
No | 26 | 171 | 1 | Â | Â | Â | Â | Â | |
TNM stage | III/IV | 25 | 48 | 16.943 | 7.262 ~ 39.528 |  < 0.001 | 16.017 | 5.830 ~  ~ 44.006 |  < 0.001 |
0/I/II | 7 | 141 | 1 | Â | Â | Â | Â | Â | |
ER |  +  | 19 | 120 | 0.723 | 0.357 ~ 1.464 | 0.367 |  |  |  |
- | 13 | 69 | 1 | Â | Â | Â | Â | Â | |
PR |  +  | 14 | 108 | 0.506 | 0.251 ~ 1.020 | 0.057 | 0.639 | 0.275 ~ 1.489 | 0.300 |
- | 18 | 81 | 1 | Â | Â | Â | Â | Â | |
HR |  +  | 19 | 124 | 0.652 | 0.322 ~ 1.321 | 0.235 |  |  |  |
- | 13 | 65 | 1 | Â | Â | Â | Â | Â | |
Her-2 |  +  | 25 | 120 | 2.261 | 0.976 ~ 5.234 | 0.057 | 1.568 | 0.652 ~ 3.774 | 0.315 |
_ | 7 | 78 | 1 | Â | Â | Â | Â | Â | |
Ki-67 |  ≥ 14% | 27 | 149 | 1.905 | 0.730 ~ 4.972 | 0.188 | 0.880 | 0.305 ~ 2.537 | 0.813 |
 < 14% | 5 | 40 | 1 |  |  |  |  |  | |
Breast surgery | BMS | 27 | 156 | 1.347 | 0.515 ~ 3.522 | 0.543 |  |  |  |
CMS | 5 | 33 | Â | Â | Â | Â | Â | Â | |
Chemotherapy | No | 1 | 9 | 1 | Â | Â | Â | Â | Â |
ACT | 17 | 142 | 0.844 | 0.112 ~ 6.363 | 0.870 |  |  |  | |
NACT + ACT | 14 | 38 | 4.177 | 0.545 ~ 32.002 | 0.209 |  |  |  | |
Radiotherapy | Yes | 27 | 101 | 5.332 | 2.051 ~ 13.862 | 0.001 | 2.186 | 0.766 ~ 6.240 | 0.144 |
No | 5 | 88 | 1 | Â | Â | Â | Â | Â | |
Endocrine therapy | Yes | 10 | 106 | 0.278 | 0.131 ~ 0.588 | 0.001 | 0.254 | 0.099 ~ 0.653 | 0.004 |
No | 22 | 83 | 1 | Â | Â | Â | Â | Â | |
Targeted therapy | Yes | 5 | 46 | 0.643 | 0.247 ~ 1.673 | 0.366 |  |  |  |
No | 27 | 143 | 1 | Â | Â | Â | Â | Â |